Diversified Formulations And API BusinessHaving both finished dosage formulations and API manufacturing creates diversified revenue channels and customer types (retail, hospitals, B2B exports). This reduces single-market concentration risk, enables cross-selling and utilization smoothing, and supports structural resilience in varied demand cycles.

Stable Gross Margins With Moderate Revenue GrowthStable gross margins across modest top-line growth indicate durable cost controls in manufacturing and procurement. Persistently healthy gross margins provide ongoing capacity to fund SG&A, R&D or capacity maintenance, supporting sustainable operations even if revenue growth remains moderate over the next several quarters.

Improving Return On EquityA trend of rising ROE suggests management is becoming more efficient at allocating capital and generating returns from equity. Improved ROE enhances internal ability to finance investments, strengthens shareholder value creation prospects and can reduce reliance on external financing over the medium term.

Bears Say

High LeverageMaterial reliance on debt raises structural financial risk: interest costs and covenant pressure can constrain strategic choices, capex and R&D. In cyclical downturns or cost inflation environments, high leverage reduces flexibility and increases probability of financing stress or dilutive recapitalization.

Inconsistent Operating And Free Cash FlowVolatile operating and free cash flows weaken the firm’s ability to fund working capital, service debt and invest organically. Structural cash-generation inconsistency increases dependency on external funding, elevates refinancing risk and limits capacity for sustained investments or dividend policies over multiple quarters.

Low Net Profit MarginPersistently low net margins indicate pressure from SG&A, interest or other non-operating costs and reduce retained earnings. Lower profitability restricts the company's ability to self-finance growth, build reserves against shocks, and weakens long-term competitiveness versus better-margin peers.

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?

Bal Pharma Limited lowest stock price was ₹64.00 and its highest was ₹128.86 in the past 12 months.

What is Bal Pharma Limited’s market cap?

Bal Pharma Limited’s market cap is ₹1.09B.

When is Bal Pharma Limited’s upcoming earnings report date?

Bal Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 77 days.

How were Bal Pharma Limited’s earnings last quarter?

Bal Pharma Limited released its earnings results on Feb 11, 2026. The company reported ₹1.118 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.118.

Is Bal Pharma Limited overvalued?

According to Wall Street analysts Bal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bal Pharma Limited pay dividends?

Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.62%. See more information on Bal Pharma Limited dividends here

What is Bal Pharma Limited’s EPS estimate?

Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bal Pharma Limited have?

Bal Pharma Limited has 15,920,872 shares outstanding.

What happened to Bal Pharma Limited’s price movement after its last earnings report?

Bal Pharma Limited reported an EPS of ₹1.118 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.072%.

Which hedge fund is a major shareholder of Bal Pharma Limited?

Currently, no hedge funds are holding shares in IN:BALPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bal Pharma Limited

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.